Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Bibliographic Details
Main Authors:	Ruth Wester, Sonja Zweegman, Bronno van der Holt, Marie José Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Emelie Asselbergs, Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Annemiek Broijl, Pieter Sonneveld
Format:	Article
Language:	English
Published:	Wiley 2020-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000370

Similar Items

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
by: Ruth Wester, et al.
Published: (2019-11-01)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
by: Henk M. Lokhorst, et al.
Published: (2008-01-01)

Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?
by: Monika Engelhardt, et al.
Published: (2019-11-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
by: Ruth Wester, et al.
Published: (2022-02-01)

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival
by: Henk M. Lokhorst, et al.
Published: (2015-12-01)

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology
by: Bouke P.C. Hazenberg, et al.
Published: (2015-05-01)

HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients
by: Monique C. Minnema, et al.
Published: (2024-08-01)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
by: Monique Minnema, et al.
Published: (2023-08-01)

Treatment of relapsed and refractory multiple myeloma
by: Pieter Sonneveld, et al.
Published: (2016-08-01)

Treatment of relapsed and refractory multiple myeloma
by: Pieter Sonneveld, et al.
Published: (2016-04-01)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
by: Kazimierz Groen, et al.
Published: (2023-09-01)

Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
by: Tong Li, et al.
Published: (2020-11-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study
by: Po‐Wei Liao, et al.
Published: (2024-05-01)

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
by: Monique C. Minnema, et al.
Published: (2019-11-01)

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
by: Sonja Zweegman, et al.
Published: (2020-02-01)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
by: K. Groen, et al.
Published: (2022-06-01)

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
by: Annemiek Broijl, et al.
Published: (2016-04-01)

Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
by: Slavisa Ninkovic, et al.
Published: (2024-01-01)

Carfilzomib induced Alveolar Hemorrhage
by: Zachary Holtzapple, et al.
Published: (2023-12-01)

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
by: Antonio Palumbo, et al.
Published: (2013-01-01)

Thalidomide, the story goes on
by: Esther Papaseit, et al.
Published: (2023-06-01)

Treatment of Aphthae with Thalidomide
by: Mahmoud Farshchian
Published: (1994-03-01)

Thalidomide in dermatology: Revisited
by: Iffat Hassan, et al.
Published: (2015-01-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma
by: Céline Schilthuizen, et al.
Published: (2007-02-01)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
by: C. Touzeau, et al.
Published: (2022-06-01)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
by: Ioanna Barla, et al.
Published: (2022-11-01)

The role of carfilzomib in relapsed/refractory multiple myeloma
by: Andrew J. Yee
Published: (2021-06-01)

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
by: Joske Ubels, et al.
Published: (2018-07-01)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
by: Marcelo Capra, et al.
Published: (2021-10-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS
by: Ecenur Guder Arslan, et al.
Published: (2023-10-01)

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
by: N. van de Donk, et al.
Published: (2023-05-01)

Signatures and Induction Principles for Higher Inductive-Inductive Types
by: Ambrus Kaposi, et al.
Published: (2020-02-01)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
by: Mirian Brink, et al.
Published: (2021-11-01)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
by: Graham H Jackson, et al.
Published: (2021-01-01)

Rasmussen Syndrome: Response to Thalidomide
by: J Gordon Millichap
Published: (2003-11-01)

Thalidomide: from tragedy to promise
by: R Stolz
Published: (2003-02-01)